Cargando…

A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society

BACKGROUND: Capecitabine maintenance therapy is safe and efficacious for early-stage triple-negative breast cancer (TNBC) patients, but the cost-effectiveness of its long-term use has not been investigated. Here, we evaluated the cost-effectiveness of capecitabine maintenance therapy, compared with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ji-Bin, Lin, Zhuo-Chen, Wong, Martin C. S., Wang, Harry H. X., Li, Mengmeng, Li, Su
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511760/ https://www.ncbi.nlm.nih.gov/pubmed/36156186 http://dx.doi.org/10.1186/s12916-022-02516-9

Ejemplares similares

Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis
por: Bai, Jie, et al.
Publicado: (2023)

The prognostic and predictive significance of cytokeratin 5/6 and epidermal growth factor receptor in metastatic triple-negative breast cancer treated with maintenance capecitabine
por: Zhu, Yiping, et al.
Publicado: (2021)

Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials
por: Ye, Feng, et al.
Publicado: (2022)

Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer
por: Xi, Xun, et al.
Publicado: (2022)

Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study
por: Li, Yi-Hui, et al.
Publicado: (2018)

Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer
por: Si, W., et al.
Publicado: (2013)

The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis
por: Huo, Xingfa, et al.
Publicado: (2021)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zhang, Zilin, et al.
Publicado: (2021)

Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis
por: Xun, Xueqiong, et al.
Publicado: (2022)

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients
por: de Boo, Leonora W., et al.
Publicado: (2022)

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis
por: Chen, Yimeng, et al.
Publicado: (2021)

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
por: LIANG, XU, et al.
Publicado: (2015)

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer
por: Pitts, Todd M., et al.
Publicado: (2020)

Is breast conservation superior to mastectomy in early stage triple negative breast cancer?
por: Saifi, Omran, et al.
Publicado: (2022)

Addition of Capecitabine to Adjuvant Chemotherapy May be the Most Effective Strategy for Patients With Early-Stage Triple-Negative Breast Cancer: A Network Meta-Analysis of 9 Randomized Controlled Trials
por: Li, Zhiyang, et al.
Publicado: (2022)

Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2021)

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
por: Lluch, Ana, et al.
Publicado: (2020)

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
por: Chun, Brie, et al.
Publicado: (2022)

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
por: Asleh, Karama, et al.
Publicado: (2023)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma
por: SAIF, MUHAMMAD WASIF, et al.
Publicado: (2014)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer
por: Chen, Xue-Lian, et al.
Publicado: (2016)

Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
por: Peng, Jingyuan, et al.
Publicado: (2018)

The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study
por: Michie, C O, et al.
Publicado: (2010)

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
por: Li, Junjie, et al.
Publicado: (2020)

Routine maintenance of emergency supplies
Publicado: (1971)

The early-stage comprehensive costs of routine PrEP implementation and scale-up in Zambia
por: Hendrickson, Cheryl, et al.
Publicado: (2022)

＜Editors’ Choice＞ Clinical impact of standardized creatinine on dose adjustment of capecitabine
por: Ito, Ayaka, et al.
Publicado: (2022)

The Iron-Inflammation Axis in Early-Stage Triple-Negative Breast Cancer
por: Duan, Fangfang, et al.
Publicado: (2022)

A Performance Evaluation System for PPP Sewage Treatment Plants at the Operation-maintenance Stage
por: Li, Xiaojuan, et al.
Publicado: (2023)

Anti-transcriptional intermediary factor-1γ antibody-positive dermatomyositis in a patient with triple-negative breast cancer treated with adjuvant capecitabine
por: Kessler, Alaina J., et al.
Publicado: (2023)

Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology
por: Freitas-Junior, Ruffo, et al.
Publicado: (2022)

Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice
por: Schneeweiss, Andreas, et al.
Publicado: (2019)

The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study
por: Sun, Xue‐Song, et al.
Publicado: (2020)

Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study
por: Shibahara, Hidetoshi, et al.
Publicado: (2022)

PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature
por: Wang, Zhihong, et al.
Publicado: (2021)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
por: Bao, Yuwen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ds2outdsjtptg6vk7os870mfbu